Synopsis: Enalapril maleate 1 is an orally active angiotensin-converting enzyme inhibitor. It
lowers peripheral vascular resistance without causing an increase in heart rate. Enalapril 10 …

Enalapril maleate is a prodrug which when administered orally is hydrolysed to release the
active converting enzyme inhibitor enalaprilat. Enalapril maleate is 60% absorbed and 40 …

Background Troponin changes over time have been suggested to allow for an early
diagnosis of cardiac injury ensuing cancer chemotherapy; cancer patients with troponin …

1 The disposition of two angiotensin converting‐enzyme inhibitor drugs was studied in
normal volunteers. One drug was enalapril maleate (MK‐421), which requires in vivo …

The reaction of the renin-angiotensin system to acute angiotensin converting enzyme
inhibition was investigated in a single-blind, crossover study in nine normal volunteers …

Synopsis Lisinopril is an orally active angiotensin-converting enzyme (ACE) inhibitor which
at dosages of 20 to 80mg once daily is effective in lowering blood pressure in all grades of …

Quantification of pharmaceutical compounds using matrix‐assisted laser
desorption/ionization (MALDI) mass spectrometry (MS) is an alternative to traditional liquid …

Enalapril, an orally-active, long-acting, nonsulphydryl angiotensin-converting enzyme (ACE)
inhibitor, is extensively hydrolysed in vivo to enalaprilat, its bioactive form. Bioactivation …

The orally active angiotensin-converting inhibitors (ACE inhibitors) such as captopril and
enalapril represent a significant therapeutic advance in the treatment of hypertension and …

The angiotensin converting enzyme inhibitors are an important therapeutic advance in the
treatment of patients with hypertension and congestive heart failure. In addition, they are …